Unhi”

    442

    A new experimental osteoporosis drug, denosumab (Amgen) has shown to reduce the risk of vertebral fractures in post-menopausal women by 68% compared with patients taking a placebo in a pivotal clinical trial.

    (Visited 27 times, 1 visits today)